Maridebart Cafraglutide: A Literature Course

This course summarises the published literature on maridebart cafraglutide, also identified in papers by its development code AMG 133. Each module states what researchers designed, measured and reported, and then ends with the limits of that evidence. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or investigational compounds. Nothing here describes how a compound should be used, and no outcome described below should be read as a promise of benefit.

The six modules move from definition and class, through mechanism and reported outcomes, to adverse events as published, pharmacokinetics, and regulatory status. A closing section lists questions the published studies did not address.

Module 1: What Maridebart Cafraglutide Is and How It Has Been Studied

Definition and class

Maridebart cafraglutide was described in the primary literature as a bispecific molecule created by conjugating glucagon-like peptide-1 (GLP-1) receptor agonist peptides to a monoclonal antibody that antagonises the glucose-dependent insulinotropic polypeptide receptor (GIPR), a construct reported as AMG 133 in preclinical and phase 1 work (PMID 38316982). A 2026 review of antibody–peptide conjugate design used maridebart cafraglutide as its principal worked example of the format, in which an antibody scaffold carries a peptide agonist payload (PMID 42592044).

Because of that architecture, the molecule is not a simple synthetic peptide in the way that the term is often used. The peptide component is the GLP-1 analogue payload; the antibody component provides both the GIPR-antagonist pharmacology and, as the design review described, the long circulation characteristic of antibodies (PMID 42592044). Broader reviews of incretin pharmacology placed it within the group of novel GLP-1-based medications developed for type 2 diabetes and obesity (PMID 41054801) and among multi-receptor agents discussed in obesity pharmacotherapy reviews (PMID 41948476).

Origin and development path

The published development path moved from animal models to early human study. The 2024 primary report described preclinical characterisation of the GIPR antagonist–GLP-1 conjugate followed by a phase 1 programme in adults, with weight and metabolic parameters as the reported endpoints (PMID 38316982). A phase 2 trial in obesity was subsequently published in 2025, with once-monthly subcutaneous administration over 52 weeks (PMID 40549887).

Forms studied

Across the published human work, the molecule was given by subcutaneous injection. The phase 2 report described monthly dosing schedules, including an arm dosed every eight weeks, rather than daily or weekly administration (PMID 40549887). No oral or intranasal formulation appears in the verified literature summarised here.

Limits of the evidence — Module 1

The identity and class description rest on a small number of primary reports plus review articles that restate them. Reviews are secondary sources and do not add independent data. Nothing in this module establishes clinical usefulness, and the phase 2 trial cited is a mid-stage study rather than a completed development programme (PMID 40549887).

Module 2: Mechanism as Described in the Literature

The mechanistic rationale reported for maridebart cafraglutide combines two actions in one molecule. The GLP-1 analogue payload engages the GLP-1 receptor, the same target as established incretin drugs, while the antibody blocks rather than activates GIPR (PMID 38316982). Researchers reported that this combination produced weight loss with improved metabolic parameters in preclinical models and in the phase 1 setting (PMID 38316982).

The GIPR "paradox"

A recurring theme in the literature is that both GIPR agonism and GIPR antagonism have been reported to support weight loss when combined with GLP-1 receptor agonism. A 2025 review examined the evidence that motivated both GIPR agonist and GIPR antagonist drug development programmes and described the unresolved tension between them (PMID 40507574). A 2026 review of GLP-1/GIP combination therapies discussed the same paradox and the proposed mechanisms offered to reconcile it (PMID 42166683).

Head-to-head mechanistic work in animals

A 2026 study directly compared GIPR agonism with GIPR antagonism on metabolic endpoints in male mice, an experimental design intended to test the two strategies under matched conditions (PMID 41287212). Such comparisons address the pharmacology of the GIPR arm in isolation rather than the clinical performance of maridebart cafraglutide itself.

Limits of the evidence — Module 2

Mechanistic accounts in reviews remain hypotheses about how observed effects arise. The mouse comparison used a single sex and species and therefore cannot be extrapolated to humans (PMID 41287212), and the paradox reviews explicitly framed the field as unsettled rather than resolved (PMID 40507574, PMID 42166683).

Module 3: Reported Outcomes by Study

This module lists the studies in the verified set, the models they used, the endpoints they measured and what the authors reported. It does not aggregate results across studies, because designs and populations differ.

The phase 2 trial in more detail

The 2025 phase 2 publication described a 52-week randomised, placebo-controlled evaluation of once-monthly subcutaneous maridebart cafraglutide in adults with obesity, with dose groups described in the report including 140 mg, 280 mg and 420 mg monthly plus a 420 mg every-eight-weeks schedule (PMID 40549887). The study reported percentage change in body weight from baseline as the primary measure and reported dose-related reductions relative to placebo at week 52 (PMID 40549887).

Class-level literature that does not test this molecule

Some reviews in the verified set discuss the incretin class in disease contexts beyond obesity. A 2026 review examined pathophysiological links between diabetes mellitus and stroke and the therapeutic potential of GLP-1 and GLP-1/GIP receptor agonists as a class (PMID 42198313). That discussion concerns a receptor class, not evidence that maridebart cafraglutide was tested for stroke-related endpoints.

Limits of the evidence — Module 3

The human evidence summarised here is early-phase. A 52-week phase 2 trial reports what happened in a selected trial population under protocol conditions and cannot establish long-term outcomes (PMID 40549887). Preclinical and phase 1 findings are hypothesis-generating (PMID 38316982), and no verified head-to-head trial against an approved incretin medicine appears in this set.

Module 4: Maridebart Cafraglutide Side Effects: What Studies Report

Adverse events are reported here only as the cited publications described them. Frequencies, severity grading and discontinuation decisions belong to those trial reports and to the clinicians who ran them.

Phase 2 trial safety reporting

In the 52-week phase 2 obesity trial, the most commonly reported adverse events were gastrointestinal — including nausea, vomiting, diarrhoea and constipation — and researchers reported that these events were predominantly mild to moderate and clustered after the first dose of each monthly schedule (PMID 40549887). The trial report also described adverse events leading to discontinuation among treated participants (PMID 40549887).

Earlier-phase safety reporting

The 2024 preclinical and phase 1 report likewise described gastrointestinal adverse events, chiefly nausea and vomiting, among the tolerability findings for the GIPR antagonist–GLP-1 conjugate in early human dosing (PMID 38316982).

Class-level context from reviews

Reviews of GLP-1-based medicines described gastrointestinal intolerance as the characteristic tolerability issue of the class and a common reason for treatment interruption (PMID 41054801). A 2026 perspective on multi-receptor obesity pharmacotherapy discussed tolerability and open safety controversies among next-generation metabolic agents (PMID 41948476).

Limits of the evidence — Module 4

Phase 1 and phase 2 populations are small and screened, so uncommon or delayed events may not appear. The phase 2 safety data cover 52 weeks and cannot describe multi-year exposure (PMID 40549887). Adverse-event profiles reported in reviews describe a receptor class, not this specific molecule (PMID 41054801).

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic discussion in the verified literature centres on the consequences of the antibody–peptide conjugate format. The 2026 design review described how anchoring a peptide payload to an antibody scaffold extends circulating exposure compared with the short half-life of native incretin peptides, and used maridebart cafraglutide to illustrate that rationale (PMID 42592044).

The clearest clinical expression of that property is the dosing interval actually studied: the phase 2 trial administered the molecule once monthly, with one arm dosed every eight weeks over 52 weeks (PMID 40549887). In the earlier programme, researchers reported that weight reduction following dosing persisted beyond the immediate dosing period, a durability the authors linked to the molecule's prolonged exposure (PMID 38316982).

Limits of the evidence — Module 5

The verified set does not contain a dedicated pharmacokinetic paper with population modelling, tissue distribution or metabolism pathways. Inferences about exposure rest on dosing intervals used in trials (PMID 40549887) and on a design-focused review rather than on primary pharmacokinetic analyses (PMID 42592044). Renal and hepatic impairment, drug–drug interaction and immunogenicity data are not covered by the sources summarised here.

Module 6: Regulatory Status

Stated factually, and without legal advice: maridebart cafraglutide is an investigational molecule. The literature summarised here consists of preclinical work, a phase 1 programme (PMID 38316982) and a phase 2 trial (PMID 40549887). No approved finished product containing maridebart cafraglutide is described in these publications, and mid-stage trial publication is not marketing authorisation.

Research-use-only material

Peptides and biologics distributed as "research use only" (RUO) are labelled for laboratory investigation and are not authorised as medicines for human administration. RUO labelling reflects the intended use of the material, not an assessment of quality, identity or sterility, and RUO status is legally distinct from the approval pathway that governs prescription medicines.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires bulk drug substances that are components of an FDA-approved drug, appear in an applicable USP or National Formulary monograph, or appear on the relevant FDA bulks list. An investigational molecule that has not received approval and is not on those lists does not meet those conditions. Requirements also vary by state board of pharmacy. This section describes published regulatory frameworks for educational purposes and is not legal advice.

Limits of the evidence — Module 6

Regulatory status changes over time and by jurisdiction, and published trial papers are not regulatory documents. Readers interested in current status would need to consult the relevant regulator's own records rather than the literature summarised here.

What the Studies Did Not Test

The verified literature leaves substantial questions unaddressed:

• Cardiovascular and stroke outcomes for this molecule. Class-level discussion of GLP-1 and GLP-1/GIP receptor agonists in stroke appears in review form (PMID 42198313), but no outcome trial of maridebart cafraglutide is included here.
• Exposure beyond one year. The longest human study summarised ran 52 weeks (PMID 40549887).
• Head-to-head comparison. No verified trial compared the molecule directly with an approved GLP-1 or dual GLP-1/GIP agonist.
• Special populations. Pregnancy, lactation, paediatric use, older adults, and renal or hepatic impairment are not covered by the cited reports.
• Weight maintenance and body composition after discontinuation. Durability after dosing stops was discussed only in early-phase terms (PMID 38316982).
• Resolution of the GIPR paradox. Reviews described agonism and antagonism as competing strategies still under investigation (PMID 40507574, PMID 42166683).

Taken together, the published record describes an investigational antibody–peptide conjugate with early human efficacy and safety data and an unusually long dosing interval. It does not describe an established therapy, and it is not a basis for personal decisions. This page remains educational only; questions about obesity treatment belong with a licensed physician.

References

• Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2025)
• A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (Nature Metabolism, 2024)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice (Diabetes, Obesity & Metabolism, 2026)
• The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms (Annual Review of Nutrition, 2026)
• Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists (Pharmaceutics, 2026)
• Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies (Metabolism Open, 2026)
• Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications (Antibody Therapeutics, 2026)
• The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs (Journal of Clinical Medicine, 2025)